Conference Announces New Pump Research


By: dhtest

Type 2s Say They Like the Pump Better

There has not been a wealth of research into whether insulin-dependent type 2s would prefer insulin-pump therapy to injection therapy. This led four researchers from Boston to conduct a study of 126 insulin-treated type 2s, which was presented at this year’s ADA scientific sessions.

The researchers report, “Type 2 patients requiring intensive-insulin therapy demonstrated greater satisfaction with the pump compared to multiple daily injections using a pen.”

For the study, 60 people were randomized to multiple subcutaneous pen injection, while 66 people were put on the pump. Patient-satisfaction questionnaires were passed out at 16 and 24 weeks into the study.

The researchers discovered that:

  • 97 percent of the type 2s using the pump preferred it to their previous injectable insulin regimen.
  • 97 percent preferred the convenience of a pump while traveling
  • 95 percent preferred its overall convenience
  • 95 percent said they obtained better blood-sugar control
  • 93 percent said they had a better feeling about themselves.

“This enhanced acceptance may improve [adherence] and facilitate the initiation of intensive insulin therapy in type 2 diabetes,” concludes the researchers.

Researchers Say Novolog Safe for Pump Use

The soon-to-be-released fast-acting insulin aspart (Novolog), according to Bruce Bode, MD, of Atlanta Diabetes Association, is “safe and effective in continuous subcutaneous insulin infusion and is suitable for use in external insulin pumps.”

Bode and researchers from around the country presented results of their study at the recent ADA scientific sessions. For their study, they randomized 146 adults with type 1 diabetes to receive either Novolog buffered regular insulin (Velosulin) or lispro (Humalog) in an external pump for 16 weeks. Before the study, all subjects had four weeks of treatment with Velosulin.

At the beginning of the study, HbA1c was similar between the treatment groups—Novolog 7.34%; Velosulin 7.47% and Humalog 7.29%. By the end of the study, the Novolog group’s A1c control remained the same, while the Velosulin and Humalog group’s A1c’s got slightly worse (7.63% and 7.47%, respectively).

The researchers note that after-meal BG values were lower in the Novolog compared to Velosulin group but similar to the Humalog group. However, they were “significantly lower 90 minutes after dinner in the [Novolog] group (136 mg/dl) when compared to the Velosulin (171 mg/dl) and Humalog (164 mg/dl) groups.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.